March 26, 2015Identification of miRNA targets in triple negative breast cancer from Latinas
Luciane R. Cavalli, PhD
Symposium on Global Cancer Research
Boston, MA
Abstract: Triple negative breast cancer (TNBC) account for 10-17% of all breast cancers and are defined by the low or lack of expression of ER, PR and HER2 receptors. These tumors are more commonly seen in younger women of African and Latinas/Hispanic descents, usually diagnosed at more advanced stages, with non-localized disease. Molecular studies have shown differences in the biology of these tumors in Latinas as key contributors for high mortality. Aims: The main goal of our study was to investigate the biological factors that may be associated with poor prognosis in a group of Latina patients with TNBC.

December 4, 2014Considerations for Sharing Clinical Trial DataErin Wilhelm, MPHAssociation of Academic Health Centers (AAHC) Annual Research MeetingWashington, DCAbstract: The generation, dissemination, and sharing of research data are key ingredients in contributing to scientific progress and the public good. Data sharing has been encouraged to facilitate open, team-based science within the clinical research enterprise, across traditional boundaries, and ultimately improve the development of medical products and benefit public health. But sharing data is complex. This presentation identifies and examines approaches and cost considerations involved in sharing participant-level clinical research data.

April 9, 2014An integrated framework for the pharmacogenomic characterization of oncological drug response to enable precision medicineKrithika Bhuvaneshwar MS, Michael Harris MA, Thanemozhi Natarajan PhD, Laura Sheahan PhD, John Deeken MD, Subha Madhavan, PhD, MSAmerican Medical Informatics Association (AMIA) Joint Summits on Translational Science San Francisco, CAAbstract: Response to the oncology drug gemcitabine may be variable in part due to genetic differences in the enzymes and transporters responsible for its metabolism and disposition. The aim of our in-silico study was to identify gene variants significantly associated with gemcitabine response that may help to personalize treatment in the clinic.

October 2, 2014GVISR: Georgetown Vaccine Information Safety ResourcePeter B. McGarvey PhD, Baris E. Suzek PhD, James N. Baraniuk MD, Shruti Rao MS, Brian Conkright MS, Samir Lababidi PhD, Andrea Sutherland MD MPH MSc, Richard Forshee PhD, Subha Madhavan PhD MSGeorgetown University Innovation Center for Biomedical InformaticsAnnual Bioinformatics Symposium 2014Washington, DC Abstract: Near universal administration of vaccines mandates intense pharmacovigilance for vaccine safety and a stringently low tolerance for adverse events. Reports of autoimmune diseases (AID) following vaccination have been challenging to evaluate given the high rates of vaccination, background incidence of autoimmunity, and low incidence and variable times for onset of AID after vaccinations. In order to identify biologically plausible pathways to adverse autoimmune events of vaccine-related AID, we used a systems biology approach to create a matrix of innate and adaptive immune mechanisms active in specific diseases, responses to vaccine antigens, adjuvants, preservatives and stabilizers, for the most common vaccine-associated AID found in the Vaccine Adverse Event Reporting System

October 2, 2014Targeting Triple Negative Breast Cancer in African American WomenSubha Madhavan PhD MS, Luciane R. Cavalli PhDGeorgetown University Innovation Center for Biomedical InformaticsAnnual Bioinformatics Symposium 2014Washington, DC Abstract: The objective of this study is to identify molecular markers in TNBC patients for drug discovery research and personalized medicine. This research will provide the infrastructure, data, and tools to analyze multi-omics data from TNBC samples to help reviewers at the FDA use this framework for new, targeted therapies in breast cancer.

September 22, 2013In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseasesPeter B. McGarvey PhD, Baris E. Suzek PhD, James N. Baraniuk MD, Shruti Rao MS, Brian Conkright MS, Samir Lababidi PhD, Andrea Sutherland MD MPH MSc, Richard Forshee PhD, Subha Madhavan PhD MSAssociation for Computing Machinery (ACM) Bioinformatics Computational Biology, and Biomedical Informatics (BCB) 2013 ConferenceWashington, DC Abstract: Near universal administration of vaccines mandates intense pharmacovigilance for vaccine safety and a stringently low tolerance for adverse events. Reports of autoimmune diseases (AID) following vaccination have been challenging to evaluate given the high rates of vaccination, background incidence of autoimmunity, and low incidence and variable times for onset of AID after vaccinations. In order to identify biologically plausible pathways to adverse autoimmune events of vaccine-related AID, we used a systems biology approach to create a matrix of innate and adaptive immune mechanisms active in specific diseases, responses to vaccine antigens, adjuvants, preservatives and stabilizers, for the most common vaccine-associated AID found in the Vaccine Adverse Event Reporting System.